Figure 5.

PTCy with BBG does not compromise GVL immunity. (a) Schematic representation of the humanised mouse model of GVHD/GVL. (a–e) NSG mice were humanised with 20 × 10⁶ human (h) PBMCs (n = 4 donors; presented as GVL groups) (or with PBS) on Day 0, treated with cyclophosphamide (33 mg/kg) or PBS (Days 3 and 4), and BBG (50 mg/kg) or saline (Days 0–10) then injected with 1 × 10⁶ THP-1 leukaemia cells (Day 14). Mice were assessed thrice weekly for (b) weight change, (c) clinical score, and (d) survival. (e) The proportions of hCD33⁺ THP-1 AML cells in liver suspensions were determined by flow cytometry. (b,c,e) Data are presented as mean ± SEM. (d) Data are presented as percent survival, χ² test for mortality. (n = 8, GVL; n = 9, GVL + PTCy + BBG; n = 10, THP-1; n = 9, THP-1 + PTCy + BBG).